The Optical Molecular Imaging and Analysis (OMIA) Shared Resource provides a variety of optical imaging services, technologies, equipment and expertise to support the scientific needs and objectives of the Duke Cancer Institute (DCI). Optical techniques have become an increasingly important tool for understanding molecular mechanisms of cancer development and therapy. Its high sensitivity and specificity enable elegant studies into gene regulation and functional processes involved in cancer progression and therapeutic response. The other key advantage of optical techniques is that they are non-invasive and relatively cost effective and so can be done serially in the same animal, allowing for better characterization of transient or dynamic effects and minimizing the overall use of animals. No other modality can provide all of these benefits.
The Optical Molecular Imaging and Analysis shared resource facilitates small animal imaging and spectroscopy. The services can be broken down broadly according to the categories below:
Services offered include:
To take advantage of the optical imaging technique we aim to surgically implant a window on different organs to be able to image them by microscope. Dr. Hanna has developed several animal surgical models, and works with investigators to develop new surgical models to fit the study goal.
These services are designed to facilitate the wide spread adoption of a wide range of technologies centered on in vivo optical imaging and spectroscopy. These technologies include:
Shared Resource: Optical Molecular Imaging and Analysis
Of all the resources available to aid in cancer research, luciferase–a group of enzymes responsible for the bioluminescent activity of fireflies and other glowing animals–seem like an unlikely candidate. Yet at the DCI’s Optical Molecular Imaging and Analysis shared resource, luciferase is fueling a variety of cancer-related research. More
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.Learn More